Ms. Abbie Lynn Olszewski, MA, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1664 N Virginia St, Redfield Medical Bldg, Reno, NV 89557 Phone: 775-784-4887 Fax: 775-784-4095 |
Melissa N Fleischmann Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 155 Country Estates Cir, Ste 200, Reno, NV 89511 Phone: 775-852-6323 Fax: 775-852-6321 |
Mrs. Amanda Michelle Mattioli, M.S., CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 2667 Enterprise Rd, Reno, NV 89512 Phone: 775-688-0372 |
Joyce Chan Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 235 W 6th St, Reno, NV 89503 Phone: 775-770-3268 |
Nancy Jane Ryman, M.A.C.C.C. Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 975 Kirman Ave, Reno, NV 89502 Phone: 775-328-1844 |
Jenna Gruppo Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 10587 Double R Blvd Ste 101, Reno, NV 89521 Phone: 775-324-5371 Fax: 775-852-5373 |
Shannon Sullivan, Ms, Ccc-slp, Llc Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 9520 Prototype Ct, Reno, NV 89521 Phone: 775-852-6323 |
John Paul G Mcguire, M.A., M.S., CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1868 Countryside Ave, Reno, NV 89523 Phone: 775-742-5288 |
Marilyn Munker, MS, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 123 Mount Rose St, Reno, NV 89509 Phone: 775-240-0667 |
Mrs. Lauren Bremer Jackson, MS CCC SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 6240 Sierra Mesa St, Reno, NV 89511 Phone: 775-525-0866 |
Nevada Educational And Therapy Solutions, Llc Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1101 W Moana Lane #7, Reno, NV 89509 Phone: 775-453-2148 |
Kylie Wiesner, CCC SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1200 Laredo Ct, Reno, NV 89503 Phone: 530-306-2547 |
Kristin Camara, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1155 Mill St, Reno, NV 89502 Phone: 775-982-4100 |
Christin Lindberg, MS, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 2667 Enterprise Rd, Reno, NV 89512 Phone: 775-720-2957 |
Nevada Speech And Therapy Group Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1380 High Chaparral Drive, Reno, NV 89521 Phone: 775-742-5288 Fax: 775-851-9231 |
Lisa Galano, M.S., CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 9520 Prototype Ct, Reno, NV 89521 Phone: 775-852-6323 Fax: 775-852-6321 |
Tomiko Ihara Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 4120 Falling Water Dr, Reno, NV 89519 Phone: 775-762-6236 |
Desert Rose Speech Therapy Llc Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 9520 Prototype Ct, Reno, NV 89521 Phone: 775-852-6323 Fax: 775-852-6321 |
Dr. Shelly L Von Berg, PHD Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1664 N Virginia, Redfield Medical Building Mail Stop 152, Reno, NV 89557 Phone: 775-784-4887 Fax: 775-784-4095 |
Heather Hansen, MS, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 343 Elm St Ste 304, Reno, NV 89503 Phone: 775-235-4320 Fax: 775-260-1724 |
News Archive
Researchers in the United States have conducted genetic correlation studies revealing novel traits associated with the development of severe coronavirus disease 2019 (COVID-19).
BGI-Shenzhen announced today that it, through its wholly-owned subsidiary Beta Acquisition Corporation, has extended its all cash tender offer to purchase all outstanding shares of common stock of Complete Genomics, Inc. to 12:00 midnight on Wednesday, February 6, 2013.
Tokai Pharmaceuticals, Inc., a biopharmaceutical company focused on developing new treatments for prostate cancer, today announced that the company raised $35.5 million in a Series E financing based on encouraging clinical progress and investor support for galeterone (TOK-001), Tokai's lead prostate cancer drug candidate.
Advaxis, Inc., a leader in developing the next generation of immunotherapies for cancer and infectious diseases, has received affirmation by the Public Health Service of the U. S. Centers for Disease Control and Prevention and the Zentrale Kommission für die Biologische Sicherheit, the Central Commission for Biological Safety in Germany, that Advaxis strains, constructs and immunotherapies have been attenuated to the point that they are classified as non-pathogenic materials for handling and shipment.
› Verified 4 days ago